Page last updated: 2024-10-22

alendronate and Primary Hyperparathyroidism

alendronate has been researched along with Primary Hyperparathyroidism in 15 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Research Excerpts

ExcerptRelevanceReference
"To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis."9.17Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. ( Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U, 2013)
"Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD)."7.77Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. ( Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011)
"To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis."5.17Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. ( Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U, 2013)
"Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD)."3.77Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. ( Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011)
" Cinacalcet and vitamin D may have a small or no increase in overall adverse events."2.82The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Bakaa, L; Bilezikian, JP; Brandi, ML; Chang, Y; Clarke, B; Couban, RJ; Guyatt, G; Khan, AA; Manja, V; Mannstadt, M; Silverberg, SJ; Sreekanta, A; Tangamornsuksun, W; Tong, K; Wang, Y; Ye, Z; Zhang, M; Zhang, Y, 2022)
"Primary hyperparathyroidism is a common endocrine disorder that results in elevated levels of parathyroid hormone and subsequent hypercalcaemia."2.53Primary hyperparathyroidism and the role of the nurse. ( Walker, J, 2016)
"Histopathologic analysis revealed a parathyroid adenoma."1.36Primary hyperparathyroidism with classic and severe skeletal involvement. ( Paz-Pacheco, E; Sandoval, MA, 2010)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (20.00)29.6817
2010's10 (66.67)24.3611
2020's2 (13.33)2.80

Authors

AuthorsStudies
Ye, Z1
Silverberg, SJ1
Sreekanta, A1
Tong, K1
Wang, Y1
Chang, Y1
Zhang, M1
Guyatt, G1
Tangamornsuksun, W1
Zhang, Y1
Manja, V1
Bakaa, L1
Couban, RJ1
Brandi, ML1
Clarke, B1
Khan, AA1
Mannstadt, M1
Bilezikian, JP1
Rajput, S1
Dutta, A1
Rajender, S1
Mithal, A1
Chattopadhyay, N1
Szymczak, J2
Bohdanowicz-Pawlak, A2
Akbaba, G1
Isik, S1
Ates Tutuncu, Y1
Ozuguz, U1
Berker, D1
Guler, S1
Minisola, S1
Cipriani, C1
Piemonte, S1
Colangelo, L1
Pepe, J1
Romagnoli, E1
Cesareo, R1
Di Stasio, E1
Vescini, F1
Campagna, G1
Cianni, R1
Pasqualini, V1
Romitelli, F1
Grimaldi, F1
Manfrini, S1
Palermo, A1
Walker, J1
Farag, N1
Delbanco, T1
Strewler, GJ1
Faggiano, A1
Di Somma, C1
Ramundo, V1
Severino, R1
Vuolo, L1
Coppola, A1
Panico, F1
Savastano, S1
Lombardi, G1
Colao, A1
Gasperi, M1
Bollerslev, J1
Marcocci, C1
Sosa, M1
Nordenström, J1
Bouillon, R1
Mosekilde, L1
Iglesias, P1
Castro, JC1
Abreu, C1
Díez, JJ1
Sandoval, MA1
Paz-Pacheco, E1
Gołkowski, F1
Barczyński, M1
Buziak-Bereza, M1
Huszno, B1
Cichoń, S1
Sugimoto, T1

Reviews

5 reviews available for alendronate and Primary Hyperparathyroidism

ArticleYear
The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022, Volume: 37, Issue:11

    Topics: Alendronate; Calcium; Cinacalcet; Denosumab; Estrogens; Humans; Hyperparathyroidism, Primary; Parath

2022
Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Deno

2023
Primary hyperparathyroidism and the role of the nurse.
    Nursing older people, 2016, Volume: 28, Issue:6

    Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Humans; Hyperca

2016
Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism.
    European journal of endocrinology, 2011, Volume: 165, Issue:6

    Topics: Alendronate; Animals; Bone Resorption; Evidence-Based Medicine; Humans; Hypercalcemia; Hyperparathyr

2011
[Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Apr-10, Volume: 96, Issue:4

    Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Calcium; Diagnosis, Differential; Diagnos

2007

Trials

2 trials available for alendronate and Primary Hyperparathyroidism

ArticleYear
Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.
    Journal of endocrinological investigation, 2013, Volume: 36, Issue:11

    Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Humans; Hyperpar

2013
Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:4

    Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cholecal

2015

Other Studies

8 other studies available for alendronate and Primary Hyperparathyroidism

ArticleYear
Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2013, Volume: 45, Issue:10

    Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-Control St

2013
Osteoprotegerin serum levels in primary hyperparathyroidism and changes following surgery.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2014, Volume: 46, Issue:5

    Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Hyperparathyroidism,

2014
Osteoprotegerin in primary hyperparathyroidism.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2014, Volume: 46, Issue:5

    Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Hyperparathyroidism,

2014
Update: A 64-year-old woman with primary hyperparathyroidism.
    JAMA, 2008, Nov-05, Volume: 300, Issue:17

    Topics: Adenoma; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Progressio

2008
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Endocrine, 2011, Volume: 39, Issue:3

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cinac

2011
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
    Medicina clinica, 2012, May-26, Volume: 138, Issue:15

    Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans

2012
Primary hyperparathyroidism with classic and severe skeletal involvement.
    BMJ case reports, 2010, Aug-26, Volume: 2010

    Topics: Adenoma; Alendronate; Calcitriol; Calcium Carbonate; Female; Follow-Up Studies; Fractures, Spontaneo

2010
[New horizons for increased sensitivity of radionuclide imaging in primary hyperparathyroidism].
    Przeglad lekarski, 2006, Volume: 63, Issue:2

    Topics: Adenoma; Adult; Alendronate; Female; Humans; Hyperparathyroidism, Primary; Image Enhancement; Middle

2006